Dr. Chien on Tucatinib in HER2+ Breast Cancer

Video

In Partnership With:

A. Jo Chien, MD, associate clinical professor, Department of Medicine, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the use of tucatinib (ONT-380) in the treatment of patients with HER2-positive breast cancer.

A. Jo Chien, MD, associate clinical professor, Department of Medicine, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the use of tucatinib (ONT-380) in the treatment of patients with HER2-positive breast cancer.

Tucatinib is one of many TKIs that possesses the potential to penetrate the blood—brain barrier, says Chien. In addition to tucatinib, lapatinib (Tykerb) and neratinib (Nerlynx) have also been looked at in the treatment of patients with brain metastases. As single agents, they have not demonstrated compelling responses, but when paired with capecitabine, these agents have shown impressive responses in the central nervous system, says Chien.

Tucatinib has also shown strong responses when paired with trastuzumab (Herceptin) and capecitabine. The unique aspect of tucatinib is that it has more preferential binding to HER2 than EGFR, and therefore, has lower rates of diarrhea, explains Chien. An issue with the TKIs has been the associated gastrointestinal toxicity. If tucatinib continues to show a safety profile that is consistent with what has been observed to date, it could fulfill a large unmet need for patients.

Related Videos
Emmanuel Antonarakis, MD, associate director, Translational Research, Masonic Cancer Center, University of Minnesota, Clark Endowed Professor of Medicine, University of Minnesota Medical School
Gautam Jha, MD, medical director, M Health Fairview Masonic Cancer Clinic and the Advanced Treatment Center at the M Health Fairview Clinics and Surgery Center—Minneapolis, chair, cancer committee, M Health Fairview Ridges Hospital
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute